News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,486 Results
Type
Article (485)
Company Profile (1)
Press Release (1000)
Section
Business (573)
Career Advice (1)
Deals (101)
Drug Delivery (5)
Drug Development (384)
Employer Resources (5)
FDA (47)
Job Trends (61)
News (925)
Policy (97)
Tag
Academia (3)
Adcomms (1)
Alliances (88)
ALS (1)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (1)
Approvals (40)
Artificial intelligence (4)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (38)
Biotechnology (1)
Cancer (6)
Career advice (2)
CAR-T (4)
CDC (1)
Cell therapy (19)
Clinical research (247)
Collaboration (1)
Complete response letters (2)
COVID-19 (10)
CRISPR (5)
C-suite (10)
Data (3)
Denatured (3)
Depression (1)
Diagnostics (5)
Diversity (3)
Drug discovery (1)
Drug pricing (5)
Duchenne muscular dystrophy (2)
Earnings (171)
Employer branding (5)
Employer resources (5)
Events (229)
Executive appointments (9)
FDA (55)
Funding (10)
Gene editing (11)
Generative AI (1)
Gene therapy (46)
GLP-1 (13)
Government (26)
Healthcare (28)
Immunology and inflammation (1)
Infectious disease (11)
Influenza (1)
IPO (55)
Job creations (21)
Job search strategy (1)
Layoffs (6)
Leadership (1)
Legal (6)
Manufacturing (7)
MASH (1)
Medical device (4)
Medtech (4)
Mergers & acquisitions (58)
Metabolic disorders (6)
Neurodegenerative disease (4)
Neuropsychiatric disorders (1)
Neuroscience (9)
NextGen: Class of 2026 (38)
Non-profit (6)
Obesity (5)
Opinion (11)
People (224)
Phase 1 (134)
Phase 2 (128)
Phase 3 (121)
Pipeline (4)
Policy (7)
Postmarket research (7)
Preclinical (17)
Psychedelics (3)
Rare diseases (24)
Real estate (22)
Recruiting (3)
Regulatory (82)
Research institute (7)
Series A (2)
Series B (1)
Sickle cell disease (17)
Special edition (1)
Spinal muscular atrophy (1)
Startups (27)
Tariffs (1)
The Weekly (12)
Vaccines (9)
Venture capital (4)
Weight loss (3)
Women's health (1)
Date
Last 30 days (1)
Last 365 days (74)
2026 (3)
2025 (74)
2024 (128)
2023 (83)
2022 (169)
2021 (185)
2020 (131)
2019 (136)
2018 (105)
2017 (120)
2016 (122)
2015 (120)
2014 (53)
2013 (24)
2012 (16)
2011 (10)
2010 (4)
Location
Africa (7)
Asia (32)
Australia (8)
California (6)
Colorado (2)
Europe (163)
Massachusetts (43)
Nevada (1)
New Jersey (2)
New York (3)
North Carolina (1)
Northern California (4)
Pennsylvania (3)
South America (7)
Southern California (2)
Texas (3)
United States (62)
Washington D.C. (1)
Washington State (1)
1,486 Results for "bluebird bio.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand
Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new path forward for manufacturing.
September 19, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer
Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.
April 16, 2025
·
1 min read
·
Dan Samorodnitsky
Deals
Bluebird’s Private Equity Buyout Boosts Upfront Cash for Shareholders
After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has a new deal to offer shareholders.
May 15, 2025
·
1 min read
Deals
Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’
Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called bluebird bio? We wanted to know.
July 2, 2025
·
7 min read
·
Annalee Armstrong
Mergers & acquisitions
Bluebird Draws Another Suitor Amid Plans To Go Private
Ayrmid’s offer is 50% higher than bluebird’s previously announced deal with Carlyle and SK Capital Partners.
March 31, 2025
·
2 min read
·
Tristan Manalac
Bankruptcy
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.
March 12, 2025
·
6 min read
·
Ana Mulero
Gene therapy
FDA Restricts Patient Pool for Bluebird’s Skysona Amid Safety Concerns
Skysona can now only be used in patients with cerebral adrenoleukodystrophy who have no available treatment alternatives or stem cell donors.
August 11, 2025
·
2 min read
·
Tristan Manalac
Podcast
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.
February 26, 2025
·
1 min read
·
Heather McKenzie
Press Releases
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots
September 18, 2025
·
4 min read
Mergers & acquisitions
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M
The proposed acquisition by global investment firms Carlyle and SK Capital Partners could net shareholders $3 per share plus potential CVR dollars and provide bluebird bio with primary capital to expand the commercial reach of its gene therapies.
February 21, 2025
·
3 min read
·
Heather McKenzie
1 of 149
Next